sur Sandoz Group AG (isin : CH1243598427)
Sandoz Launches Enzeevu in US to Expand Retinal Treatment Options
Sandoz Group AG has announced the US launch of Enzeevu, a biosimilar treatment for various retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and macular edema. Approved by the FDA in August 2024, Enzeevu provides an affordable option for over 30 million Americans affected by these conditions. The launch is part of Sandoz's strategy to enhance its biosimilar portfolio under its Bio100 ambition.
The introduction of Enzeevu, delivered via a pre-filled syringe, aims to improve patient access to retinal care, addressing treatment costs, a significant barrier. Enzeevu shows clinical equivalence to Eylea, the reference medicine, fulfilling all FDA biosimilarity criteria. It is interchangeable with the reference for all approved indications, supporting cost-effective healthcare.
Sandoz has also secured a multi-year private-label agreement to expand Enzeevu's reach in the US market, commencing mid-2027. This aligns with Sandoz’s history of successful private-label biosimilars. The agreement ensures committed volumes from the second half of 2027, strengthening Sandoz’s position in the ophthalmology sector.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Sandoz Group AG